| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
225,410,000 |
| Market
Cap: |
159.48(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4783 - $1.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8 |
| Insider 3/6 Months : 8.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Co.'s clinical-stage product candidates include: Seralutinib, also known as GB002, which is an inhaled small molecule, platelet-derived growth factor receptor colony-stimulating factor 1 receptor and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, which is an oral small molecule for the treatment of inflammatory bowel disease; and GB5121, which an oral small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
232,000 |
232,000 |
1,400,505 |
| Total Buy Value |
$0 |
$138,093 |
$138,093 |
$2,465,139 |
| Total People Bought |
0 |
2 |
2 |
5 |
| Total Buy Transactions |
0 |
2 |
2 |
12 |
| Total Shares Sold |
44,068 |
44,068 |
45,882 |
93,276 |
| Total Sell Value |
$52,319 |
$52,319 |
$54,659 |
$345,585 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
5 |
5 |
6 |
15 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hasnain Faheem |
President & CEO |
• • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
162,500 |
162,500 |
|
- |
|
| Christian Waage |
EVP & General Counsel |
• – – |
2020-10-14 |
4 |
B |
$9.53 |
$23,818 |
I/I |
2,500 |
6,954 |
1.99 |
11% |
|
| Giraudo Bryan |
Chief Financial Officer |
• – – |
2020-10-14 |
4 |
B |
$10.01 |
$30,036 |
I/I |
3,000 |
7,121 |
1.99 |
11% |
|
| Hasnain Faheem |
Director |
– • – |
2020-10-14 |
4 |
B |
$10.36 |
$999,995 |
I/I |
96,520 |
3,478,629 |
2.1 |
11% |
|
| Giraudo Bryan |
Chief Financial Officer |
• – – |
2020-06-23 |
4 |
B |
$12.96 |
$25,922 |
I/I |
2,000 |
4,121 |
1.99 |
-33% |
|
| Gujrathi Sheila |
President & CEO |
• • – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
189,500 |
189,500 |
|
- |
|
| Christian Waage |
EVP & General Counsel |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
46,500 |
547,998 |
|
- |
|
| Giraudo Bryan |
Chief Financial Officer |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
46,500 |
70,379 |
|
- |
|
| Dupont Jakob |
Chief Medical Officer |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
46,500 |
46,500 |
|
- |
|
| Salter-Cid Luisa |
Chief Scientific Officer |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
46,500 |
166,556 |
|
- |
|
| Salter-Cid Luisa |
Chief Scientific Officer |
• – – |
2019-12-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,000 |
120,056 |
|
- |
|
| Dupont Jakob |
Chief Medical Officer |
• – – |
2019-12-30 |
4 |
S |
$15.00 |
$600,004 |
D/D |
(40,000) |
0 |
|
-4% |
|
| Dupont Jakob |
Chief Medical Officer |
• – – |
2019-12-30 |
4 |
OE |
$10.71 |
$428,400 |
D/D |
40,000 |
40,000 |
|
- |
|
| Dupont Jakob |
Chief Medical Officer |
• – – |
2019-12-27 |
4 |
S |
$15.81 |
$31,534 |
D/D |
(1,994) |
0 |
|
- |
|
| Dupont Jakob |
Chief Medical Officer |
• – – |
2019-12-27 |
4 |
OE |
$10.71 |
$21,356 |
D/D |
1,994 |
1,994 |
|
- |
|
| Christian Waage |
EVP & General Counsel |
• – – |
2019-09-27 |
4 |
B |
$16.65 |
$16,654 |
I/I |
1,000 |
4,454 |
1.99 |
- |
|
| Gujrathi Sheila |
President & CEO |
• • – |
2019-09-27 |
4 |
B |
$16.80 |
$167,980 |
I/I |
10,000 |
4,048,242 |
2.66 |
- |
|
| Hasnain Faheem |
Director |
– • – |
2019-09-27 |
4 |
B |
$16.80 |
$167,980 |
I/I |
10,000 |
3,382,109 |
2.1 |
- |
|
| Giraudo Bryan |
Chief Financial Officer |
• – – |
2019-09-26 |
4 |
B |
$16.78 |
$18,810 |
I/I |
1,121 |
2,121 |
1.99 |
- |
|
| Omega Fund V Gp Manager, Ltd. |
10% Owner |
– – • |
2019-09-20 |
4 |
S |
$21.96 |
$4,032,561 |
D/D |
(183,607) |
6,553,416 |
|
- |
|
| Stampacchia Otello |
Former director. |
– – • |
2019-09-18 |
4 |
S |
$21.88 |
$997,637 |
D/D |
(45,600) |
6,737,023 |
|
- |
|
| Stampacchia Otello |
Former director. |
– – • |
2019-09-17 |
4 |
S |
$21.62 |
$505,791 |
D/D |
(23,400) |
6,782,623 |
|
- |
|
| Stampacchia Otello |
Former director. |
– – • |
2019-09-16 |
4 |
S |
$21.52 |
$284,331 |
D/D |
(13,213) |
6,806,023 |
|
- |
|
| Stampacchia Otello |
Director |
– • • |
2019-09-11 |
4 |
S |
$21.31 |
$1,713,629 |
D/D |
(80,403) |
6,819,236 |
|
- |
|
| Stampacchia Otello |
Director |
– • • |
2019-09-10 |
4 |
S |
$21.00 |
$679,865 |
D/D |
(32,373) |
6,899,639 |
|
- |
|
91 Records found
|
|
Page 3 of 4 |
|
|
